Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Hormones, Outcomes, and Pain Pathways in Exercise Study (HOPE)

28. mai 2026 oppdatert av: Stacey Gorniak, University of Houston

Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women

The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.

Studieoversikt

Detaljert beskrivelse

Approximately 130 million individuals in the US (39% of the US population) are living with chronic musculoskeletal pain. Women experience more localizations of pain across their lifespan. Women report significantly more pain in the neck, shoulders, arms, back, and breasts due to altered musculoskeletal activity within in the neck and thoracic region due to the presence of breast tissue. Neck, shoulder, arm, and back (NSAB) pain has been strongly linked to bra cup size. Since 2000, there has been a significant increase in women's average bra cup size from B to E; women with cup sizes D and above are considered "full-busted". Most commercially available sport bras are designed for low- to medium-impact activities for women with cup size C or smaller, leaving women with cup sizes of D or larger without adequate breast support during physical activity. While the primary source of NSAB pain in these women is likely mechanical, evidence suggests non-mechanical pain pathways that may contribute to pain expression in women. Specifically, evidence of sex-hormone influences, systemic inflammation, and cortical remapping in female animal models with respect to chronic musculoskeletal pain is emerging; however, characterization of the influences of sex-hormone levels, inflammation, and concurrent cortical changes in the somatosensory and motor regions particularly in reference to chronic NSAB pain in women across the lifespan is a major gap in the evidence base. This critical gap in understanding physiological and neurological sex differences in chronic NSAB pain manifestation in full-busted women will be filled by our proposed project. In this project, the investigators will evaluate a non-pharmacological (mechanical) intervention to alleviate NSAB pain in full-busted women and investigate non-mechanical pathways associated with chronic NSAB pain in women. The investigators will measure both self-reported and objective measures of pain in conjunction with objective measures of behavior and blood-based measures to assess: (1) the impact of the mechanical intervention and (2) non-mechanical factors contributing to chronic musculoskeletal pain in women. The findings from this project will advance multifactorial understanding of pain in full-busted women, a population that lives with chronic musculoskeletal pain.

Studietype

Intervensjonell

Registrering (Antatt)

140

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Stacey L Gorniak, PhD
  • Telefonnummer: 713-743-4802
  • E-post: sgorniak@uh.edu

Studiesteder

    • Texas
      • Houston, Texas, Forente stater, 77204
        • Rekruttering
        • University of Houston
        • Ta kontakt med:
          • Stacey L Gorniak, PhD
          • Telefonnummer: 713-743-4802
          • E-post: sgorniak@uh.edu
        • Hovedetterforsker:
          • Stacey L Gorniak, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  1. Able to provide informed consent
  2. Age of 18 to 60 years
  3. Assigned female sex at birth
  4. Right-handed by self-declaration
  5. Willing to participate in one online testing session and up to four in-person testing sessions
  6. Bra band size between 32-40"
  7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher
  8. An answer of "NO" to any item of the general health questions of the PARQ+
  9. No history of surgery to the: back, neck, or shoulders or joint replacement
  10. No history of implanted pacemakers or other stimulation devices
  11. No history of spinal cord injury (SCI)

Exclusion Criteria:

  1. Inability to provide informed consent
  2. Age 17 years old or younger or 61 years or older
  3. Assigned male sex at birth
  4. Left-handed by self-declaration
  5. Not willing to participate in one online testing session and up to four in-person testing sessions
  6. Bra band size greater than 40" or less than 32"
  7. IPAQ-SF score of 1 or lower
  8. An answer of "YES" to any item of the general health questions of the PARQ+
  9. History of limb amputation (upper or lower extremity)
  10. Presence of open pressure sores on the upper or lower extremities
  11. Currently pregnant or lactating/breastfeeding
  12. History of surgery to the: back, neck, or shoulders or joint replacement
  13. History of breast cancer and/or mastectomy
  14. History of implanted pacemakers or other stimulation devices
  15. History of spinal cord injury (SCI)
  16. History of joint disease including osteoarthritis and/or Rheumatoid Arthritis
  17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and/or Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies

Additional Inclusion Criteria for Intervention Group:

a. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)

Additional Inclusion Criteria for the Control Group:

a. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Control
Women with bra cup sizes A - C. Control group will undergo measurement of kinematic and kinetic data during physical activities at baseline. Study questionnaires, pain measures, body composition, brain activity, and blood-based biomarkers will be collected at baseline. Physical activity will be tracked via smartwatch for 3 months after baseline.
Eksperimentell: Interventional Sports Bra
Women with bra cup sizes D - I. Intervention group will undergo measurement of kinematic and kinetic data during physical activities at baseline and 3 months after receiving their interventional sports bras. Study questionnaires, pain measures, body composition, brain activity, and blood-based biomarkers will be collected at baseline and 3 months after receiving the interventional sports bras. Physical activity will be tracked via smartwatch for 3 months after baseline.
This study involves use of observation and analysis of behavior in assessing breast motion and associated health outcomes while using a provided interventional sports bra of participant choice (Bounceless bra or Shefit Ultimate bra) for 3 months.
Andre navn:
  • Bounceless bra
  • Shefit Ultimate bra

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain Measures
Tidsramme: Baseline and 3 months after baseline
Qualitative assessment of pain via self-report (no units)
Baseline and 3 months after baseline
Objective Pain Measure
Tidsramme: Baseline and 3 months after baseline
Nociceptive Flexion Reflex Threshold (mV)
Baseline and 3 months after baseline
Physical activity
Tidsramme: Baseline and 3 months after baseline
Frequency and duration of physical activity as measured via smartwatch
Baseline and 3 months after baseline
Anthropometry
Tidsramme: Baseline and 3 months after baseline
Percent body fat (%)
Baseline and 3 months after baseline
Anthropometry
Tidsramme: Baseline and 3 months after baseline
Body mass index (BMI) (kg/m²)
Baseline and 3 months after baseline
Glycated Hemoglobin
Tidsramme: Baseline and 3 months after baseline
A1c (%)
Baseline and 3 months after baseline
Lipids
Tidsramme: Baseline and 3 months after baseline
Total Cholesterol (mg/dL)
Baseline and 3 months after baseline
Lipids
Tidsramme: Baseline and 3 months after baseline
High Density Lipoprotein Cholesterol (HDL) (mg/dL)
Baseline and 3 months after baseline
Biomechanical Data
Tidsramme: Baseline and 3 months after baseline
Muscle activity (mV)
Baseline and 3 months after baseline
Neuroimaging Data
Tidsramme: Baseline and 3 months after baseline
Oxygenated Hemoglobin (HbO) (p-value)
Baseline and 3 months after baseline
Neuroimaging Data
Tidsramme: Baseline and 3 months after baseline
Deoxygenated Hemoglobin (HbR) (p-value)
Baseline and 3 months after baseline

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Blood Pressure
Tidsramme: Baseline and 3 months after baseline
Systole and Diastole (mmHg)
Baseline and 3 months after baseline
Systemic Inflammation Index
Tidsramme: Baseline and 3 months after baseline
SII (no units)
Baseline and 3 months after baseline
Neuroimaging Data
Tidsramme: Baseline and 3 months after baseline
Total Hemoglobin (HbT) (p-value)
Baseline and 3 months after baseline
Biomechanical Data
Tidsramme: Baseline and 3 months after baseline
Breast tissue acceleration (m/s2)
Baseline and 3 months after baseline
Biomechanical Data
Tidsramme: Baseline and 3 months after baseline
Gait speed (m/s)
Baseline and 3 months after baseline
Biomechanical Data
Tidsramme: Baseline and 3 months after baseline
Cadence (Hz)
Baseline and 3 months after baseline
Menopausal Status
Tidsramme: Baseline
Age at menopause (years) - if applicable
Baseline
Sex-Hormones
Tidsramme: Baseline and 3 months after baseline
Testosterone (mg/dL)
Baseline and 3 months after baseline
Sex-Hormones
Tidsramme: Baseline and 3 months after baseline
Estradiol (mg/dL)
Baseline and 3 months after baseline
Sex-Hormones
Tidsramme: Baseline and 3 months after baseline
Progesterone (mg/dL)
Baseline and 3 months after baseline
Sex-Hormones
Tidsramme: Baseline and 3 months after baseline
Follicle Stimulating Hormone (mg/dL)
Baseline and 3 months after baseline
Sex-Hormones
Tidsramme: Baseline and 3 months after baseline
Sex Hormone Binding Globulin (nmol/L)
Baseline and 3 months after baseline

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Stacey L Gorniak, PhD, University of Houston

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. mai 2026

Primær fullføring (Antatt)

1. juni 2029

Studiet fullført (Antatt)

1. september 2029

Datoer for studieregistrering

Først innsendt

4. mai 2026

Først innsendt som oppfylte QC-kriteriene

4. mai 2026

Først lagt ut (Faktiske)

12. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

What data outputs will the research generate?

Biomechanical Evaluation Data Blood-based Biomarker Data (e.g., inflammation markers, sex-hormone values) Health State Data (e.g., blood pressure values, BMI, body composition values, menopausal status) Pain Data Physical Activity Data Functional Neuroimaging Data (t-values of Cortical Oxygenated, Deoxygenated, and Total Hemoglobin)

Manuscripts (which will also be publicly available via Pubmed upon publication)

IPD-delingstidsramme

Data will be available as soon as possible but no later than within one year of the completion of the funded project period or upon acceptance of specific data for publication. Data will be available for 5 years after the completion of the funded project.

Tilgangskriterier for IPD-deling

Deidentified data will be made available to the research community via Zenodo. Potential data users must agree to: (1) credit the original study, study team, and investigators; (2) protect study participants by limiting data use to scientific research and aggregate statistical reporting; (3) will not attempt to identify and/or contact study participants, and (4) will agree not to share or redistribute any data downloads.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere